Summary
GBI Research, the leading
business intelligence provider, has released its latest research, "NSCLC
Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on
Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool",
which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC)
indication. The report provides an estimation of the market size for 2012 along
with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering
Australia, China, India and Japan. It also covers disease epidemiology,
treatment algorithms, treatment patterns, clinical trial analysis (including
failure rates), pipeline analysis, and analysis of deals relevant to NSCLC.
View
Full Report with TOC @ http://www.radiantinsights.com/research/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool
The NSCLC market in the APAC
region is estimated to have been worth $1.8 billion in 2012 and is expected to
grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by
2019. The key drivers for this growth include an aging population, an
increasing number of NSCLC incident cases and the expected launch of promising
therapies. The launch of premium-priced novel antibodies and immunotherapies in
the first and second lines of therapy, including Boehringer Ingelheim's
Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab)
and nivolumab, Pfizer's dacomitinib and Novartis's LDK378 are set to drive the
market during the forecast period. However, the recent implementation of a
price ceiling on essential drugs,dominance of generic drugs in India and
expected pricing restrictions in China could curtail the NSCLC market in APAC
countries.
Scope
The report analyzes treatment
usage patterns, market characterization, pipeline analysis and key licensing
and co-development deals in Australia, China, India and Japan. It includes -
- A brief introduction to NSCLC,
including the disease's pathogenesis, etiology, diagnosis and treatment
algorithms
- In-depth analysis of currently
marketed drugs for NSCLC, including analysis of their safety, efficacy,
treatment patterns and strengths and weaknesses, as well as a heat map
comparing them in terms of safety and efficacy
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
Blog
URL: http://radiantinsights.weebly.com/
No comments:
Post a Comment